Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its development pipeline, noting, “We observed continued demand across our commercial portfolio and expanded our manufacturing capabilities.” The positive market reaction followed management’s focus on execution despite ongoing pricing dynamics and competitive pressures in select product lines.

Is now the time to buy AMPH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

• Ekaterina Knyazkova (JPMorgan) asked about future R&D and SG&A spending, and volatility in gross margins. CFO Bill Peters explained that remediation and new product launches would drive costs higher, but gross margins should remain similar to Q2 levels.
• Yuchen Ding (Jefferies) inquired about the IMS facility’s FDA warning letter and its revenue exposure. CFO Peters clarified that IMS accounts for about a third of sales, with no current plans to halt production, while regulatory remediation continues.
• Naoki Martin (Piper Sandler) questioned whether business development priorities favored immediately accretive acquisitions or tolerance for late-stage assets. Peters responded that Amphastar prefers accretive or near-term accretive deals, but will consider late-stage assets if strategically aligned.
• John Gionco (Needham & Company) sought updates on ipratropium bromide’s market share targets and glucagon’s outlook. Peters confirmed strong initial uptake for ipratropium bromide and expects glucagon’s decline to moderate, with no growth anticipated.
• Melanie (BofA Securities) asked about anticipated margins for the insulin aspart biosimilar. Peters said margins would likely be at or slightly below current corporate levels due to competitive pricing.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will monitor (1) execution of IMS facility remediation and any related operational disruptions, (2) progress on pipeline milestones such as regulatory filings and new clinical trial initiations, and (3) continued uptake for newly launched products like ipratropium bromide. Additionally, shifts in pricing dynamics for core brands and the impact of manufacturing investments will be important signposts for Amphastar’s execution.

Amphastar Pharmaceuticals currently trades at $20.28, up from $19.81 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.